Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

NCT03339843 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Adenocarcinoma
Esophagus SCC
Cholangiocarcinoma
Urothelial/Bladder Cancer, Nos
Endometrial Cancer

Interventions

DRUG: Abemaciclib

Sponsor

Jules Bordet Institute

Collaborators

[object Object]